Title Category Credit Event date Costsort descending
ONS Bridge — Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
09/10/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
ONS Bridge — Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
09/17/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
07/30/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Adaptive Protocols and Practical Strategies for the Use of Novel Anticoagulation Reversal Agents
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
09/09/2020 $0.00 This interprofessional, community Grand Rounds initiative is targeted to addressing the professional practice of physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals, who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications.
Precision Therapy in NSCLC: Pharmacist Perspectives on Testing Strategies and Biomarker-Driven Treatment Approaches
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
New Horizons in HER2+ Breast Cancer: Pharmacist-Focused Strategies and Insights
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.
Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.
EGFR Resisters Virtual Poster Walk
$0.00 We would like to provide patients, advocates, and others in the lung cancer community with a curated list of abstracts that may be of interest as you peruse the vast amount of data online at am.asco.org.
Anticoagulation Reversal for Life-threatening Bleeding: A Case-based Presentation for the Critical Care Team
  • Cardiology
$0.00 Click here to complete this activity 
Pharmacist Perspectives: Exploring the Evolving Role of BTK Inhibitors in CLL
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored.

Pages